Based on the inclusion and exclusion criteria, 225 patients were divided according to their KRAS status between Arm A (88 patients with one or more KRAS mutations) and Arm B (137 patients with KRAS wild-type colorectal cancer). This evidence concerns the gene KRAS and colorectal cancer.